Review



e faecalis v583  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC e faecalis v583
    Bacterial strains and their sensitivities to phage EFLK1, vancomycin and combined treatment.
    E Faecalis V583, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 741 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/Enterococcus+faecalis/pmc06833023-50-1-4
    Average 99 stars, based on 741 article reviews
    e faecalis v583 - by Bioz Stars, 2026-11
    99/100 stars

    Images

    1) Product Images from "Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin"

    Article Title: Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin

    Journal: Viruses

    doi: 10.3390/v11100954

    Bacterial strains and their sensitivities to phage EFLK1, vancomycin and combined treatment.
    Figure Legend Snippet: Bacterial strains and their sensitivities to phage EFLK1, vancomycin and combined treatment.

    Techniques Used: Isolation

    Representative depiction of vancomycin minimal inhibitory concentration (MIC) for E. faecalis V583 (VRE) by serial dilutions. The results are mean ± SD based on three independent biological replicates.
    Figure Legend Snippet: Representative depiction of vancomycin minimal inhibitory concentration (MIC) for E. faecalis V583 (VRE) by serial dilutions. The results are mean ± SD based on three independent biological replicates.

    Techniques Used: Concentration Assay

    Treatment of planktonic bacteria with 1.2 × 10 8 plaque forming units (PFU)/well phage EFLK1 (anti- E. faecalis phage) combined with 0.015 mg/mL vancomycin reduced VRE growth. Total growth was inhibited in the combination of 0.015 mg vancomycin/mL and 1.2 × 10 8 PFU/well phage EFLK1 (red). VRE control depicts untreated bacteria showing maximal growth (blue). A longer lag phase was observed after treatment with 0.015 mg/mL vancomycin (green) or phage EFLK1 (1.2 × 10 8 PFU/well) alone (purple). The combined treatment reduced the bacterial maximum optical density (OD) with better effect than that of the phages or vancomycin alone. The results are mean ± SD based on 3 independent biological replicates.
    Figure Legend Snippet: Treatment of planktonic bacteria with 1.2 × 10 8 plaque forming units (PFU)/well phage EFLK1 (anti- E. faecalis phage) combined with 0.015 mg/mL vancomycin reduced VRE growth. Total growth was inhibited in the combination of 0.015 mg vancomycin/mL and 1.2 × 10 8 PFU/well phage EFLK1 (red). VRE control depicts untreated bacteria showing maximal growth (blue). A longer lag phase was observed after treatment with 0.015 mg/mL vancomycin (green) or phage EFLK1 (1.2 × 10 8 PFU/well) alone (purple). The combined treatment reduced the bacterial maximum optical density (OD) with better effect than that of the phages or vancomycin alone. The results are mean ± SD based on 3 independent biological replicates.

    Techniques Used: Bacteria, Control

    Viable counts of planktonic vancomycin-resistant E. faecalis following a combined treatment of phage EFLK1 and vancomycin. The colony forming units (CFU)/mL of VRE treated with 0.015 mg/mL vancomycin combined with phage EFLK1 1.2 × 10 8 PFU/well is presented. Bacteria were below the limit of detection after treating the cells by combining phage EFLK1 and vancomycin. Bacteria treated only with vancomycin showed survival scores like those of the untreated bacteria; cells treated with phage EFLK1 showed medium survival rates. Combining vancomycin and phage EFLK1 caused seven log reductions in CFU/mL. Light gray = vancomycin-treated bacteria, dark gray = phage EFLK1 treatment, black = phage EFLK1 + vancomycin. Statistically significant ( p < 0.01) compared to the untreated control. The results are mean ± SD based on three independent biological replicates.
    Figure Legend Snippet: Viable counts of planktonic vancomycin-resistant E. faecalis following a combined treatment of phage EFLK1 and vancomycin. The colony forming units (CFU)/mL of VRE treated with 0.015 mg/mL vancomycin combined with phage EFLK1 1.2 × 10 8 PFU/well is presented. Bacteria were below the limit of detection after treating the cells by combining phage EFLK1 and vancomycin. Bacteria treated only with vancomycin showed survival scores like those of the untreated bacteria; cells treated with phage EFLK1 showed medium survival rates. Combining vancomycin and phage EFLK1 caused seven log reductions in CFU/mL. Light gray = vancomycin-treated bacteria, dark gray = phage EFLK1 treatment, black = phage EFLK1 + vancomycin. Statistically significant ( p < 0.01) compared to the untreated control. The results are mean ± SD based on three independent biological replicates.

    Techniques Used: Bacteria, Control

    E. faecalis biofilm biomass following treatment with phage EFLK1 (1.2 × 10 8 PFU/well) and vancomycin (0.015 mg/mL). Treatment with combinations of phage EFLK1 and vancomycin significantly decreased bacterial biomass (87% reduction) as evaluated by crystal violet staining. The results are presented as percentages, normalized to the biofilm biomass controls. Light gray = vancomycin-treated bacteria, dark gray = phage EFLK1 treatment served as the control, black = phage EFLK1 + vancomycin treatment. Statistically significant ( p < 0.05) compared to the untreated control. The results are mean ± SD based on three independent biological replicates.
    Figure Legend Snippet: E. faecalis biofilm biomass following treatment with phage EFLK1 (1.2 × 10 8 PFU/well) and vancomycin (0.015 mg/mL). Treatment with combinations of phage EFLK1 and vancomycin significantly decreased bacterial biomass (87% reduction) as evaluated by crystal violet staining. The results are presented as percentages, normalized to the biofilm biomass controls. Light gray = vancomycin-treated bacteria, dark gray = phage EFLK1 treatment served as the control, black = phage EFLK1 + vancomycin treatment. Statistically significant ( p < 0.05) compared to the untreated control. The results are mean ± SD based on three independent biological replicates.

    Techniques Used: Staining, Bacteria, Control

    Combinations of phage EFLK1 and vancomycin target VRE. Scanning electron microscopy images (MAG: A – C : 20,000, D : 2000): ( A ) E. faecalis 72-h biofilm. ( B ) Biofilm exposed to vancomycin alone, showing no effect. ( C ) E. faecalis biofilm exposed to phage EFLK1 showing bacterial lysis, leaving mainly the extracellular matrix. ( D ) E. faecalis biofilm exposed to vancomycin and phage EFLK1 showing massive bacterial lysis, degradation and biofilm deformation, leaving almost no trace of biofilm.
    Figure Legend Snippet: Combinations of phage EFLK1 and vancomycin target VRE. Scanning electron microscopy images (MAG: A – C : 20,000, D : 2000): ( A ) E. faecalis 72-h biofilm. ( B ) Biofilm exposed to vancomycin alone, showing no effect. ( C ) E. faecalis biofilm exposed to phage EFLK1 showing bacterial lysis, leaving mainly the extracellular matrix. ( D ) E. faecalis biofilm exposed to vancomycin and phage EFLK1 showing massive bacterial lysis, degradation and biofilm deformation, leaving almost no trace of biofilm.

    Techniques Used: Electron Microscopy, Lysis

    Alexa Fluor 647 wheat germ agglutinin (WGA) stains EFLK1 survivors . Confocal microscopy images (MAG: 60): ( A – B ) vancomycin resistant E. faecalis V583 show low fluorescence level, indicating no conjugation to N -acetylglucosamine. ( C – D ) EFLK1 survivors show high fluorescence levels followed the conjugation of Alexa Fluor 647 WGA to N -acetylglucosamine.
    Figure Legend Snippet: Alexa Fluor 647 wheat germ agglutinin (WGA) stains EFLK1 survivors . Confocal microscopy images (MAG: 60): ( A – B ) vancomycin resistant E. faecalis V583 show low fluorescence level, indicating no conjugation to N -acetylglucosamine. ( C – D ) EFLK1 survivors show high fluorescence levels followed the conjugation of Alexa Fluor 647 WGA to N -acetylglucosamine.

    Techniques Used: Confocal Microscopy, Fluorescence, Conjugation Assay

    Fluorescence activated cell sorting (FACS) analysis: higher fluorescence levels are obtained followed phage treatment. Red = EFLK1 survivors, black = untreated control of E. faecalis V583. Statistically significant ( p < 0.01) compared to the untreated control. The results are mean ± SD based on six independent biological replicates.
    Figure Legend Snippet: Fluorescence activated cell sorting (FACS) analysis: higher fluorescence levels are obtained followed phage treatment. Red = EFLK1 survivors, black = untreated control of E. faecalis V583. Statistically significant ( p < 0.01) compared to the untreated control. The results are mean ± SD based on six independent biological replicates.

    Techniques Used: Fluorescence, FACS, Control

    Related Articles

    Control:

    Article Title: [2601.22382] Purely Agentic Black-Box Optimization for Biological Design
    Article Snippet: .. The bacterial panel utilized in this study consisted of the following pathogenic strains: Acinetobacter baumannii ATCC 19606; A. baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem); Escherichia coli ATCC 11775; E. coli AIC221 [MG1655 phnE 2::FRT, polymyxin-sensitive control]; E. coli AIC222 [MG1655 pmrA53 phnE 2::FRT, polymyxin-resistant]; E. coli ATCC BAA-3170 (resistant to colistin and polymyxin B); E. coli K-12 BW25113; Enterobacter cloacae ATCC 13047; Klebsiella pneumoniae ATCC 13883; K. pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem); Pseudomonas aeruginosa PAO1; P. aeruginosa PA14; P. aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, β-lactams, and carbapenems); Salmonella enterica ATCC 9150; S. enterica subsp. enterica Typhimurium ATCC 700720; Bacillus subtilis ATCC 23857; Staphylococcus aureus ATCC 12600; S. aureus ATCC BAA-1556 (methicillin-resistant); Enterococcus faecalis ATCC 700802 (vancomycin-resistant); and Enterococcus faecium ATCC 700221 (vancomycin-resistant). ..

    Article Title: A deep reinforcement learning platform for antibiotic discovery
    Article Snippet: .. The pathogenic strains utilized included Acinetobacter baumannii ATCC 19606, Acinetobacter baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem), Escherichia coli ATCC 11775, Escherichia coli AIC221 [MG1655 phnE_2::FRT, polymyxin-sensitive control], E. coli AIC222 [MG1655 pmrA53 phnE_2::FRT, polymyxin-resistant], Escherichia coli ATCC BAA-3170 (resistant to colistin and polymyxin B), Enterobacter cloacae ATCC 13047, Klebsiella pneumoniae ATCC 13883, Klebsiella pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem), Pseudomonas aeruginosa PAO1, Pseudomonas aeruginosa PA14, Pseudomonas aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, beta-lactams, and carbapenems), Salmonella enterica ATCC 9150, Salmonella enterica subsp. enterica Typhimurium ATCC 700720, Bacillus subtilis ATCC 23857, Staphylococcus aureus ATCC 12600, Staphylococcus aureus ATCC BAA-1556 (resistant to methicillin), Enterococcus faecalis ATCC 700802 (resistant to vancomycin), and Enterococcus faecium ATCC 700221 (resistant to vancomycin). ..

    Article Title: Designing AI-programmable therapeutics with the EDEN family of foundation models
    Article Snippet: .. The bacterial panel utilized in this study consisted of the following pathogenic strains: Acinetobacter baumannii ATCC 19606; A. baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem); Escherichia coli ATCC 11775; E. coli AIC221 [MG1655 phnE_2::FRT, polymyxin-sensitive control]; E. coli AIC222 [MG1655 pmrA53 phnE_2::FRT, polymyxin-resistant]; E. coli ATCC BAA-3170 (resistant to colistin and polymyxin B); E. coli K-12 BW25113; Enterobacter cloacae ATCC 13047; Klebsiella pneumoniae ATCC 13883; K. pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem); Pseudomonas aeruginosa PAO1; P. aeruginosa PA14; P. aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, β-lactams, and carbapenems); Salmonella enterica ATCC 9150; S. enterica subsp. enterica Typhimurium ATCC 700720; Bacillus subtilis ATCC 23857; Staphylococcus aureus ATCC 12600; S. aureus ATCC BAA-1556 (methicillin-resistant); Enterococcus faecalis ATCC 700802 (vancomycin-resistant); and Enterococcus faecium ATCC 700221 (vancomycin-resistant). ..

    Article Title: Enterococcus-derived cytolysin exacerbates ischemic stroke by disrupting the blood-brain barrier via NLRP3 activation.
    Article Snippet: .. To investigate the effects of cytolysin in vivo, mice were orally gavaged once daily for 14 consecutive days with 5 × 108 colony-forming units (CFU) of either a cytolysin-positive Enterococcus faecalis strain (CylPE.f, ATCC#29212), a cytolysin-negative Enterococcus faecalis strain (CylNE.f, ATCC#700802), or PBS as a vehicle control, as described in previous research [18]. ..

    Article Title: [2510.01988] PepCompass: Navigating peptide embedding spaces using Riemannian Geometry
    Article Snippet: .. J.2 Bacterial Strains and Growth Conditions The bacterial panel utilized in this study consisted of the following pathogenic strains: Acinetobacter baumannii ATCC 19606; A. baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem); Escherichia coli ATCC 11775; E. coli AIC221 [MG1655 phnE_2::FRT, polymyxin-sensitive control]; E. coli AIC222 [MG1655 pmrA53 phnE_2::FRT, polymyxin-resistant]; E. coli ATCC BAA-3170 (resistant to colistin and polymyxin B); Enterobacter cloacae ATCC 13047; Klebsiella pneumoniae ATCC 13883; K. pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem); Pseudomonas aeruginosa PAO1; P. aeruginosa PA14; P. aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, β-lactams, and carbapenems); Salmonella enterica ATCC 9150; S. enterica subsp. enterica Typhimurium ATCC 700720; Bacillus subtilis ATCC 23857; Staphylococcus aureus ATCC 12600; S. aureus ATCC BAA-1556 (methicillin-resistant); Enterococcus faecalis ATCC 700802 (vancomycin-resistant); and Enterococcus faecium ATCC 700221 (vancomycinresistant). ..

    Bacteria:

    Article Title: PepGlider: Property Regularized VAE for interpretable and controllable peptide design
    Article Snippet: .. The dataset includes measurements against Gram-negative bacteria ( Acinetobacter baumannii ( A. baumannii ) ATCC 19606, E. coli ATCC 11775, E. coli AIC221, carbapenem-resistant E. coli AIC222, Klebsiella pneumoniae ( K. pneumoniae ) ATCC 13883, Pseudomonas aeruginosa ( P. aeruginosa ) PAO1 and PA14) and Gram-positive bacteria ( S. aureus ATCC 12600, MRSA ATCC BAA-1556, vancomycin-resistant Enterococcus faecalis ( E. faecalis ) ATCC 700802, and vancomycin-resistant Enterococcus faecium ( E. faecium ) ATCC 700221). ..

    Isolation:

    Article Title: Electrospun Phage-Loaded Bilayer Nanofibrous Scaffolds for Wound Dressing Applications: A Comparative Study of Different Bacteriophages
    Article Snippet: .. Enterococcus faecalis ATCC 700802 (American Type Culture Collection; ATCC, Manassas, VA, USA) was used for the isolation and propagation of the APTC-Efa.20 bacteriophage as previously described [ ]. ..

    In Vivo:

    Article Title: Enterococcus-derived cytolysin exacerbates ischemic stroke by disrupting the blood-brain barrier via NLRP3 activation.
    Article Snippet: .. To investigate the effects of cytolysin in vivo, mice were orally gavaged once daily for 14 consecutive days with 5 × 108 colony-forming units (CFU) of either a cytolysin-positive Enterococcus faecalis strain (CylPE.f, ATCC#29212), a cytolysin-negative Enterococcus faecalis strain (CylNE.f, ATCC#700802), or PBS as a vehicle control, as described in previous research [18]. ..

    other:




    Similar Products

    96
    Olympus image data
    Image Data, supplied by Olympus, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/MVX10+Macro+Zoom+Fluorescence+Microscope+System/pm41285771-388-1-9
    Average 96 stars, based on 1 article reviews
    image data - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc fluorescence microscope data
    Fluorescence Microscope Data, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/pmc12618221-257-2-15
    Average 86 stars, based on 1 article reviews
    fluorescence microscope data - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    90
    10X Genomics spaceranger, which is a full analysis pipeline designed specifically for visium data alongside brightfield or fluorescence microscope images
    Spaceranger, Which Is A Full Analysis Pipeline Designed Specifically For Visium Data Alongside Brightfield Or Fluorescence Microscope Images, supplied by 10X Genomics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/spaceranger++which+is+a+full+analysis+pipeline+designed+specifically+for+visium+data+alongside+brightfield+or+fluorescence+microscope+images/pmc11394603-156-23-31
    Average 90 stars, based on 1 article reviews
    spaceranger, which is a full analysis pipeline designed specifically for visium data alongside brightfield or fluorescence microscope images - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    99
    Olympus confocal fluorescence imaging data
    Confocal Fluorescence Imaging Data, supplied by Olympus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/FV3000+Confocal+Laser+Scanning+Microscope/10__1021_slash_acssuschemeng__2c06268____sc2c06268_si_001-85-0-8
    Average 99 stars, based on 1 article reviews
    confocal fluorescence imaging data - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Danaher Inc computer code data collection leica confocal fluorescence microscope software
    Computer Code Data Collection Leica Confocal Fluorescence Microscope Software, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/LAS+X+Life+Science+Microscope+Software+Platform/pm32895528-468-8-12
    Average 99 stars, based on 1 article reviews
    computer code data collection leica confocal fluorescence microscope software - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Hitachi Ltd scanning electron microscopy hitachi sem su8000 x ray fluorescence technique horiba xgt 7200 x ray analytical microscope data analysis
    Scanning Electron Microscopy Hitachi Sem Su8000 X Ray Fluorescence Technique Horiba Xgt 7200 X Ray Analytical Microscope Data Analysis, supplied by Hitachi Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/SU8600/pm31886330-25-0-4
    Average 99 stars, based on 1 article reviews
    scanning electron microscopy hitachi sem su8000 x ray fluorescence technique horiba xgt 7200 x ray analytical microscope data analysis - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    97
    Bruker Corporation axio imager m1 fluorescence microscope data analysis bruker compass dataanalysis 4 0 software
    Axio Imager M1 Fluorescence Microscope Data Analysis Bruker Compass Dataanalysis 4 0 Software, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/MM2/10__1038_slash_s41557___019___0317___7-206-51-58
    Average 97 stars, based on 1 article reviews
    axio imager m1 fluorescence microscope data analysis bruker compass dataanalysis 4 0 software - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    90
    Photonics Inc fluorescent/inverted microscope, ccd camera and data acquisition using touptek view
    Fluorescent/Inverted Microscope, Ccd Camera And Data Acquisition Using Touptek View, supplied by Photonics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescence+microscope+data/fluorescent+inverted+microscope++ccd+camera+and+data+acquisition+using+touptek+view/pmc05111180-172-18-22
    Average 90 stars, based on 1 article reviews
    fluorescent/inverted microscope, ccd camera and data acquisition using touptek view - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results